Background: Curcumin is a small-molecular-weight compound that is isolated from the commonly used spice turmeric. In animal models, curcumin and its derivatives have been shown to inhibit the progression of chemically induced colon and skin cancers. The genetic changes in carcinogenesis in these organs involve different genes, but curcumin is effective in preventing carcinogenesis in both organs. A possible explanation for this finding is that curcumin may inhibit angiogenesis. Materials and Methods: Curcumin was tested for its ability to inhibit the proliferation of primary endothelial cells in the presence and absence of basic fibroblast growth factor (bFGF), as well as its ability to inhibit proliferation of an immortalized endothelial cell line. Curcumin and its derivatives were subsequently tested for their ability to inhibit bFGF-induced comeal neovas-
Introduction
Curcumin is a carotenoid pigment found in the rhizome of Curcuma longa, source of turmeric (1, 2) . Turmeric is a major component of the diet of the Indian subcontinent. Administration of curcumin to mice treated with skin and colon carcinogens has been shown to result in a decreased incidence and size of tumors compared with control mice (3) (4) (5) (6) (7) . The exact mechanism of curcumin's chemopreventive activities is not fully understood. Curcumin has been demon-strated to inhibit several signal transduction pathways, including those involving protein kinase C, the transcription factor NF-kB, phospholipase A2 bioactivity, arachidonic acid metabolism, antioxidant activity, and epidermal growth factor (EGF) receptor autophosphorylation (8) (9) (10) (11) (12) . Precisely how inhibition of these pathways relates to curcumin's antitumor effect is uncertain.
Colon and skin cancers are major public health problems in Westernized nations. Hereditary colon cancers account for up to 20% of colon carcinoma in the United States. Several genes have been shown to contribute to colon carcinogenesis in human disease and transgenic mice (13) (14) (15) . These syndromes are usually autosomal dominant, and they include familial adenomatous polyposis and nonpolyposis syndromes. In mice, phospholipase A2 expression has been demonstrated to be a co-factor in genetically susceptible mice (15) . In addition, deletion of the cyclooxygenase 2 gene in colon carcinoma-prone Apc mice results in suppression of intestinal polyposis (16) . Loss of p53 and activation of ras oncogenes appear later in tumor progression (17, 18) . Human skin cancers constitute the most common form of human neoplasia and are increasing in incidence, primarily as a result of sun exposure. In contrast to colon carcinoma, mutations of the p53 gene are felt to arise early in ultraviolet-induced cutaneous carcinogenesis. Given that curcumin has protective effects against both colon and skin cancer, but the genes involved in tumor progression of skin and colon cancer differ, we hypothesized that the antitumor effects of curcumin may be due in part to angiogenesis inhibition.
Here we demonstrate that curcumin inhibits basic fibroblast growth factor (bFGF)-induced proliferation of endothelial cells in vitro and angiogenesis in vivo. We also tested the effect of curcumin analogs with known differential chemopreventive activities on in vivo angiogenesis. Our findings indicate that inhibition of angiogenesis may underlie in part the antitumor activity of curcumin in vivo.
Materials and Methods
Endothelial Proliferation Assays Bovine capillary endothelial cells were isolated according to the method of Folkman et al. (19) and were plated at a concentration of 10 (21) . The pellet was advanced to the end of the pocket. Erythromycin ointment was placed on the operated eye to prevent infection. Eyes were examined by slit lamp on days 3-6 after implantation under general anesthesia. Corneal angiogenesis is assayed through two measurements. The first measurement, vessel length, is the length of the vessel from the corneal limbus as it grows toward the bFGF pellet. Clock hours is a measurement of neovascularized area of the cornea. The cornea is viewed as a circle that can be divided as a clock, with a maximum of 12 hr. Thus, a measurement of 3 clock hours implies that one-quarter of the cornea is vascularized. This system of measurement was established by Kenyon et al. (21) .
RNAse Protection for VEGF HaCaT keratinocytes (22) were grown in (DMEM) (JRH) supplemented with 5% FCS (Hyclone, Logan, UT) in 25 cm2 flasks. One hour prior to stimulation with 12-0-tetradecanoylphorbol-1 3-acetate (TPA), cells were switched to serumless media supplemented with 10 ,uM curcumin or an equal quantity of ethanol (final concentration 0.1 %). TPA was added to a final concentration of 5 ng/ml and incubated for 3 hr at 370C. Cells were harvested and RNA extracted with guanidinium thiocyanate/phenol.
A plasmid containing the coding region of human vascular endothelial growth factor (VEGF) 121 was obtained from H. Weich (University of Freiburg, Germany), and used to generate P32-labeled antisense riboprobe as per manufacturers protocols (Ambion, Austin, TX). RNAse protection assays were performed according to the method of Hod (23) . Protected fragments were separated on gels of 5 (Fig. 2) .
Curcumin Analogs Inhibit bFGF-Induced Neovascularization in the Mouse Cornea Curcumin analogs were assayed for their ability to inhibit bFGF-induced corneal neovascularization as described above. All analogs showed inhibitory activity, with demethoxycurcumin showing the greatest activity on both clock hours and vessel length, tetrahydrocurcumin having the least effect on clock hours, and bisdemethoxycurcumin having the least effect on vessel length (Fig. 3) . All of the curcumin derivates showed significant inhibition of bFGF-mediated neovascularization compared with control pellets. (6, 7, 12) . Curcumin has also been shown to inhibit phorbol ester-indtuced ornithinie decarboxylase, a marker of cellular proliferation and ttumorigeniesis, ilt IOitiSe skiin. In addition, curcumini has an inhibitory effect on expression of c-fos and c-juu1, oncogeInes that form the transcriptioin factor AP-1 (8, 10 tion of ornithine decarboxylase and promotion of mouse skin initiated with 7,12-dimethylbenzanthracene (DMBA) (6) . These derivatives also inhibited phorbol ester-mediated transformation of JB6 cells (8) . The saturated derivative tetrahydrocurcumin was less active than the unsaturated derivatives in these assays. These curcumin analogs were placed into corneal pellets and assayed for angiogenesis inhibition. Pure curcumin, demethoxycurcumin, tetrahydrocurcumin, and bisdemethoxycurcumin were all active in inhibiting bFGF-induced corneal neovascularization, but to varying degrees. Curcumin, demethoxycurcumin, and bisdemethoxycurcumin are much more effective chemopreventive agents than tetrahydrocurcumin in vivo (6) , although all of the derivatives have antiangiogenic activity. This may be due to other activities of curcumin, such as the ability to induce phase II detoxifying enzymes, which may inhibit further tumor promotion. All of the unsaturated curcumin derivatives have approximately equal potencies in induction of phase II enzymes, whereas the fully saturated tetrahydrocurcumin has little ability to induce phase II enzymes. Angiogenesis inhibitors may be divided into two classes. The first class, or direct angiogenesis inhibitors, refer to those agents which are relatively specific for endothelial cells and have little effect on tumor cells (28) . Examples of these include soluble VEGF receptor antagonists and angiostatin (29, 30) . Indirect inhibitors may not have direct effects on endothelial cells but may down-regulate the production of an angiogenesis stimulator, such as VEGF (20, 31) . VEGF has been shown to be up-regulated during chemically induced skin carcinogenesis; this is likely due to activation of oncogenes, such as H-ras (20, 32, 33) . Examples of indirect inhibitors of angiogenesis include inhibitors of ras-mediated signal transduction, such as farnesyltransferase inhibitors (33) . The antagonism of bFGF-mediated corneal neovascularization by curcumin and its derivatives suggests that curcumin is a direct angiogenesis inhibitor. The lack of inhibition of TPA-mediated VEGF production further supports the role of curcumin as a direct angiogenesis inhibitor.
Chemopreventive agents are a diverse group of compounds with multiple activities. These include inhibition of proliferation, enhancement of DNA repair, and induction of detoxifying enzymes, such as quinone reductase, for the removal of mutagenic xenobiotics (34). Fotsis et al. have found that the chemopreventive agent genistein can inhibit the proliferation of endothelial cells in vitro (35) . We show that curcumin, another chemopreventive agent, is capable of inhibiting bFGF-mediated angiogenesis in vivo. The precise mechanism of how chemopreventive agents actually prevent neoplasia is not fully understood. Inhibition of angiogenesis may underlie in part the beneficial activity of chemopreventive agents.
